WO2004044000A3 - Compounds and methods for modulating functions of classical cadherins - Google Patents

Compounds and methods for modulating functions of classical cadherins Download PDF

Info

Publication number
WO2004044000A3
WO2004044000A3 PCT/CA2003/001746 CA0301746W WO2004044000A3 WO 2004044000 A3 WO2004044000 A3 WO 2004044000A3 CA 0301746 W CA0301746 W CA 0301746W WO 2004044000 A3 WO2004044000 A3 WO 2004044000A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulating agents
methods
cell adhesion
compounds
adhesion recognition
Prior art date
Application number
PCT/CA2003/001746
Other languages
French (fr)
Other versions
WO2004044000A2 (en
Inventor
Orest W Blaschuk
Stephanie Denise Michaud
Original Assignee
Adherex Technologies Inc
Orest W Blaschuk
Stephanie Denise Michaud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adherex Technologies Inc, Orest W Blaschuk, Stephanie Denise Michaud filed Critical Adherex Technologies Inc
Priority to CA002504768A priority Critical patent/CA2504768A1/en
Priority to EP03775019A priority patent/EP1562986A2/en
Priority to AU2003283155A priority patent/AU2003283155A1/en
Publication of WO2004044000A2 publication Critical patent/WO2004044000A2/en
Publication of WO2004044000A3 publication Critical patent/WO2004044000A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Modulating agents and methods for enhancing or inhibiting classical cadherin-mediated functions are provided. The modulating agents comprise at least a tryptophan-containing cell adhesion recognition sequence of a classical cadherin molecule, a conservative analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a cell adhesion recognition sequence. Modulating agents may additionally comprise one or more cell adhesion recognition sequences recognized by cadherins and/or other adhesion molecules. Such modulating agents may, but need not, be linked to a targeting agent, pharmaceutically active substance and/or support material.
PCT/CA2003/001746 2002-11-14 2003-11-14 Compounds and methods for modulating functions of classical cadherins WO2004044000A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002504768A CA2504768A1 (en) 2002-11-14 2003-11-14 Compounds and methods for modulating functions of classical cadherins
EP03775019A EP1562986A2 (en) 2002-11-14 2003-11-14 Compounds and methods for modulating functions of classical cadherins
AU2003283155A AU2003283155A1 (en) 2002-11-14 2003-11-14 Compounds and methods for modulating functions of classical cadherins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42619402P 2002-11-14 2002-11-14
US60/426,194 2002-11-14

Publications (2)

Publication Number Publication Date
WO2004044000A2 WO2004044000A2 (en) 2004-05-27
WO2004044000A3 true WO2004044000A3 (en) 2004-07-22

Family

ID=32313119

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/001746 WO2004044000A2 (en) 2002-11-14 2003-11-14 Compounds and methods for modulating functions of classical cadherins

Country Status (5)

Country Link
US (1) US7456153B2 (en)
EP (1) EP1562986A2 (en)
AU (1) AU2003283155A1 (en)
CA (1) CA2504768A1 (en)
WO (1) WO2004044000A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007013304A (en) * 2005-04-26 2007-12-13 Pfizer P-cadherin antibodies.
WO2006116737A2 (en) * 2005-04-28 2006-11-02 Mcgill University Compounds and methods for modulating cadherin-mediated processes
WO2008039525A2 (en) * 2006-09-27 2008-04-03 Adherex Technologies, Inc. Cadherin antagonists in combination with anticancer agents for use in cancer treatment
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
EP2830659A1 (en) 2012-03-27 2015-02-04 Novartis AG Treatment of fibrosis
DK2941195T3 (en) * 2013-01-02 2017-03-06 Fibrotx Oü Device for measuring analytes in the skin
BR112016030740A2 (en) 2014-07-01 2018-02-20 Pfizer Inc. bispecific heterodimeric bodies and their uses
CR20170200A (en) 2014-11-14 2017-07-03 Novartis Ag ANTIBODY-FARMACO CONJUGATES
WO2016100301A1 (en) 2014-12-15 2016-06-23 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders
US10494345B2 (en) 2017-10-03 2019-12-03 Zonula, Inc. Modulators of cell adhesion, methods and compositions therefor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018098A1 (en) * 1990-05-16 1991-11-28 Genetics Institute, Inc. Bone and cartilage inductive proteins
EP0821060A2 (en) * 1996-07-24 1998-01-28 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Diagnosis and therapy of human malign tumors based on E-cadherin mutations
WO2000020607A2 (en) * 1998-10-07 2000-04-13 Stryker Corporation Chimaeric proteins between members of tgf-beta superfamily

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079600A (en) 1987-03-06 1992-01-07 Schnur Joel M High resolution patterning on solid substrates
US5245012A (en) 1990-04-19 1993-09-14 The United States Of America As Represented By The Secretary Of The Army Method to achieve solubilization of spider silk proteins
CA2078961A1 (en) 1992-04-21 1993-10-22 John Wick Two-hand pouch patch application
GB2273044B (en) 1992-12-02 1997-04-09 Pacific Chem Co Ltd Medicinal patches for percutaneous administration
US5613958A (en) 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5417224A (en) 1993-05-19 1995-05-23 Advanced Medical Instruments, Inc. Tampon and method for manufacturing the same
US6562786B1 (en) 1996-07-12 2003-05-13 Mcgill University Compounds and methods for modulating apoptosis
US6417325B1 (en) 1996-07-12 2002-07-09 Mcgill University Compounds and methods for cancer therapy
US6346512B1 (en) 1996-07-12 2002-02-12 Mcgill University Compounds and methods for modulating cell adhesion
US6207639B1 (en) 1996-07-12 2001-03-27 Mcgill University Compounds and methods for modulating neurite outgrowth
WO1998002452A2 (en) 1996-07-12 1998-01-22 Mcgill University Compounds and methods for modulating cell adhesion
US6169071B1 (en) 1996-07-12 2001-01-02 Mcgill University Compounds and methods for modulating cell adhesion
US6333307B1 (en) 1996-07-12 2001-12-25 Mcgill University Compounds and method for modulating neurite outgrowth
US6465427B1 (en) 1996-07-12 2002-10-15 Mcgill University Compounds and methods for modulating cell adhesion
US6203788B1 (en) 1997-09-29 2001-03-20 Adherex Inc. Compounds and methods for regulating cell adhesion
US6248864B1 (en) 1997-12-31 2001-06-19 Adherex Technologies, Inc. Compounds and methods and modulating tissue permeability
US6472367B1 (en) 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
EP1075494A2 (en) 1998-05-05 2001-02-14 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US6277824B1 (en) 1998-07-10 2001-08-21 Adherex Technologies Compounds and methods for modulating adhesion molecule function
US6294153B1 (en) 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
US6303576B1 (en) 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression
US6391855B1 (en) 1999-06-02 2002-05-21 Adherex Technologies, Inc. Compounds and methods for modulating junctional adhesion molecule-mediated functions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018098A1 (en) * 1990-05-16 1991-11-28 Genetics Institute, Inc. Bone and cartilage inductive proteins
EP0821060A2 (en) * 1996-07-24 1998-01-28 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Diagnosis and therapy of human malign tumors based on E-cadherin mutations
WO2000020607A2 (en) * 1998-10-07 2000-04-13 Stryker Corporation Chimaeric proteins between members of tgf-beta superfamily

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BLASCHUK O W ET AL: "CADHERINS AS MODULATORS OF ANGIOGENESIS AND THE STRUCTURAL INTEGRITY OF BLOOD VESSELS", CANCER AND METASTASIS REVIEWS, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, vol. 19, no. 1/2, 2000, pages 1 - 5, XP001041650, ISSN: 0167-7659 *
BLASCHUK O W ET AL: "IDENTIFICATION OF A CADHERIN CELL ADHESION RECOGNITION SEQUENCE", DEVELOPMENTAL BIOLOGY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 139, no. 1, 1 May 1990 (1990-05-01), pages 227 - 229, XP002050189, ISSN: 0012-1606 *
GUILFORD P: "E-CADHERIN DOWNREGULATION IN CANCER: FUEL ON THE FIRE?", MOLECULAR MEDICINE TODAY, ELSEVIER, CAMBRIDGE, GB, vol. 5, no. 4, April 1999 (1999-04-01), pages 172 - 177, XP001155310, ISSN: 1357-4310 *
JANKOWSKI J A Z ET AL: "Alterations in classical cadherins associated with progression in ulcerative and Crohn's colitis", LABORATORY INVESTIGATION, UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, BALTIMORE,, US, vol. 78, no. 9, September 1998 (1998-09-01), pages 1155 - 1167, XP002963523, ISSN: 0023-6837 *
LI GANG ET AL: "N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 61, no. 9, 1 May 2001 (2001-05-01), pages 3819 - 3825, XP002210619, ISSN: 0008-5472 *
NOË V ET AL: "Inhibition of adhesion and induction of epithelial cell invasion by HAV-containing E-cadherin-specific peptides.", JOURNAL OF CELL SCIENCE. GB, vol. 112 ( Pt 1), January 1999 (1999-01-01), pages 127 - 135, XP002282729, ISSN: 0021-9533 *
NOLLET F ET AL: "Phylogenetic analysis of the cadherin superfamily allows identification of six major subfamilies besides several solitary members", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 299, no. 3, 9 June 2000 (2000-06-09), pages 551 - 572, XP004469037, ISSN: 0022-2836 *
PUROHIT S ET AL: "Impaired E-cadherin expression in human spermatozoa in a male factor infertility subset signifies E-cadherin-mediated adhesion mechanisms operative in sperm-oolemma interactions", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 316, no. 3, 9 April 2004 (2004-04-09), pages 903 - 909, XP004495974, ISSN: 0006-291X *
ROSENBERG P ET AL: "A POTENTIAL ROLE OF R-CADHERIN IN STRIATED MUSCLE FORMATION", DEVELOPMENTAL BIOLOGY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 187, no. 1, 1997, pages 55 - 70, XP001153801, ISSN: 0012-1606 *
See also references of EP1562986A2 *

Also Published As

Publication number Publication date
WO2004044000A2 (en) 2004-05-27
CA2504768A1 (en) 2004-05-27
US7456153B2 (en) 2008-11-25
EP1562986A2 (en) 2005-08-17
AU2003283155A1 (en) 2004-06-03
US20050129676A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
WO2000002917A3 (en) Compounds and methods for modulating cadherin-mediated functions
BRPI0516727A (en) methods for treating a cd30 positive lymphoma, for inhibiting the growth of a cd30 expressing cell, and for treating or preventing a disease
EA200700813A1 (en) TRANSPORTING SUBSTANCES, DERIVATIVES OF KUPREDOXIN AND METHODS OF THEIR APPLICATION
EA200701053A1 (en) PRODUCT CONVENTIONS
WO2004076644A3 (en) A composition for delivering an agent to a target cell and uses thereof
HUP0300246A2 (en) Delivery system
WO2006038208A3 (en) Agents capable of downregulating an msf-a - dependent hif-1α and use thereof in cancer treatment
BR0013825A (en) Forms of presentation of tramadol
WO2004048411A3 (en) Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
WO2005082341A3 (en) NON-PEPTIDYL AGENTS WITH pHSP20-LIKE ACTIVITY, AND USES THEREOF
TNSN07264A1 (en) Organic compounds
YU9404A (en) Peptide-based multimeric targeted contrast agents
TNSN07304A1 (en) Combination of xolair with immunosuppressive agent
HK1089190A1 (en) Rasgap derived peptide for selectively killing cancer cells
WO2004044000A3 (en) Compounds and methods for modulating functions of classical cadherins
NO20074623L (en) Method of peptide synthesis
WO2007053570A3 (en) A polypeptide complex of trpm8 and calmodulin and its uses thereof
IL187489A (en) Substrate for an rpn11 metalloprotease comprising a jamm motif
MX2009012316A (en) Methods of treating cognitive disorders by inhibition of gpr12.
EA200602155A1 (en) A NEW COMBINATION OF THE ITOK SINUS KNOTE INHIBITOR AND THE ANGIOTENZIN TRANSFORMING ENZYME INHIBITOR AND PHARMACEUTICAL COMPOSITIONS ITS CONTAINING
WO2004029214A3 (en) Lfa-1 alpha subunit antibodies and methods of use
WO2004005881A3 (en) Methods for identification of compounds modulating insulin resistance
AU6435700A (en) Cyclic peptidomimetic urokinase receptor antagonists
WO2006002195A3 (en) Method of complexing a protein by the use of a dispersed system and proteins thereof
WO2008076916A3 (en) Thallium-sensitive agents and methods of using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2504768

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003283155

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003775019

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003775019

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP